Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Entinostat in MDS after DNMTi failure
NCT02936752Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of entinostat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by National Cancer Institute. Started Jun 2017; status: completed.
02
Drugs
entinostat
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02936752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936752.